Erik Lundin

Articles in journals

• Lundin, E. , Axelsson, S. & Ohlsson-Nevo, E. (2024). Open or closed: Experience of head and neck radiotherapy masks - A mixed-methods study.  Journal of Medical Radiation Sciences. [BibTeX]
• Johansson, B. , Staby Olsén, J. , Karlsson, L. , Lundin, E. & Lennernäs, B. (2021). High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center.  Journal of Contemporary Brachytherapy, 13 (3), 245-253. [BibTeX]
• Lundin, E. , Reizenstein, J. , Landström, F. , Bergqvist, M. , Lennernas, B. O. & Ahlgren, J. (2021). Radiotherapy as Elective Treatment of the Node-negative Neck in Oral Squamous Cell Cancer.  Anticancer Research, 41 (7), 3489-3498. [BibTeX]
• Lundin, E. , Bergqvist, M. , Ahlgren, J. , Reizenstein, J. & Lennernäs, B. (2019). Validation of a Clinical Cancer Register at the Head and Neck Oncology Center in Orebro.  Anticancer Research, 39 (1), 285-289. [BibTeX]
• Hallqvist, A. , Bergström, S. , Björkestrand, H. , Svärd, A. , Ekman, S. , Lundin, E. , Holmberg, E. , Johansson, M. & et al. (2018). Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial.  Lung Cancer, 122, 180-186. [BibTeX]

Conference papers

• Nyman, J. , Bergström, S. , Björkestrand, H. , Svärd, A. , Ekman, S. , Lundin, E. , Holmberg, E. , Johansson, M. & et al. (2018). Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial. In:  Journal of Thoracic Oncology. Elsevier. [BibTeX]